chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within 2-3 minutes of receiving shot, I felt "not present" and detached from my body. "Unreal" feeling, worse than recovering from nitrous oxide and Novocain after dental surgery.  Five minutes after shot, the left side of my face became tingly and swollen - from my chin, lips, eye socket, up to my scalp. Tingle and numbness spread to entire back of my head and down the whole left side of my body.  This sensation lasted approximately 30 minutes.    At 15 minutes, I was checked by a paramedic for hives, tongue swelling and my oxygen level (oximeter).  They did not administer any medicine to counteract.   They observed me for another 15 minutes and sent me home with instructions to take Benadryl and a nap.  Unable to drive myself home. I slept for 3 hours.  Was lethargic and exhausted.
30 minutes after receiving the shot, I became very lightheaded and dizzy, feeling like I was going to faint.  This occurred while driving, after waiting 15 minutes and leaving the facility.  I became very hot and started sweating, too.  The feeling of faintness lasted for about 20 minutes, then improved.  I felt lethargic, mildly dizzy, and generally foggy for several hours afterwards.
This spontaneous case reported by a healthcare professional, describes the occurrence of blurry vision in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 023C21A) for COVID-19 immunization. No medical history reported. On May 3, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On May 3, 2021, after the mRNA-1273 (Moderna COVID-19 vaccine), patient experienced blurry vision. At the time of the report, blurry vision: resolving. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. The reporter did not provide any causality assessments. Reporter stated the patient received his first dose of vaccine. After 2 hours he experienced blurry vision, which lasted for 2-3 weeks. The patient visited an optometrist who said there was nothing out of ordinary upon evaluating the patient's eyes. Patient's blurriness was 90% resolved. He had no medical conditions nor does he take any medications. No treatment information provided.
the muscle was very tight and stiff; the muscle was very tight and stiff; fatigued; a fever of 100.5 developed; my arm was very sore; This is a spontaneous report from a non-contactable nurse (patient). A 25-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), via an unspecified route of administration in the right arm on 02Jan2021 11:15 at single dose for COVID-19 immunization. There was no medical history. The patient has no known allergies. The patient was not pregnant. The patient's concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The patient got the vaccine Saturday, by 1500 her arm was very sore. Sunday morning her arm was so sore she could hardly move it the muscle was very tight and stiff. She was also very fatigued all day Sunday (03Jan2021) and slept most of the day, a fever of 100.5 developed. When she woke up Monday morning the fever was gone, fatigue was gone and the soreness in her arm felt like normal soreness after a vaccine such as the flu vaccine. Come Wednesday her arm was finally not sore anymore. The patient did not received treatment for the events. The outcome of the events was recovered on Jan2021.  No follow-up attempts are possible. No further information is expected.
COVID-19 symptoms started on 06/10/22; tested positive same day. It felt like allergy symptoms and I would just say I had a little bit of a sore throat from coughing and congestion. Symptoms lasted 5 days. Doctor prescribed PAXLOVID which I did take.
This spontaneous case report was received from a registered nurse professional regarding unknown number of patients of unknown age and gender. No concurrent conditions and medical histories of the patients were not reported. On an unknown date the patient was vaccinated with the vaccine GARDASIL 9 stored outside the recommended temperature range (0.3 degree for 45 minutes with a lot number # L013429 (expiry date: 08-MAY-2017), L013429 (expiry date: 21-JUN-2017), L020015 (16-AUG-2017), (dosing regimen, strength, route and frequency was unknown). Concomitant medications of the patients were not reported. No adverse event was reported. This is one of the several reports from the same source. Additional information has been requested.
This spontaneous report was received from a medical assistant, concerning multiple unspecified patients of an unknown age and gender. The patients' medical history, concurrent conditions, concomitant medications, drug reactions or allergies were not reported. On an unspecified date, the patients were vaccinated with improperly stored doses of ZOSTAVAX with lot number M041511 and expiration date on 08-JAN-2018 (strength, dose, route of administration or anatomical location were not provided) for prophylaxis; which was reconstituted with a properly store sterile diluent (manufacturer unknown). The storage temperatures were 47 to 77 degrees Fahrenheit (°F) (47 °F) for a time frame of 21 minutes and 6 to 14 degrees Fahrenheit (°F) (9°F) for 42 minutes. There was no previous temperature excursion. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same source. As of 25-AUG-2017, all telephone attempts to obtain follow-up information have been unsuccessful. Sender's Comments: US-009507513-1708USA013008: US-009507513-1708USA013009: US-009507513-1708USA013010: US-009507513-1708USA013011: US-009507513-1708USA013012: US-009507513-1707USA005187: US-009507513-1708USA013006: US-009507513-1708USA013005: US-009507513-1708USA013007.
patient has not had any symptoms.; an expired dose of PROQUAD was inadvertently given to a patient on 6/19/2023.; This spontaneous report was received from a healthcare worker regarding a patient of an unknown age and gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 19-JUN-2023, the patient was inadvertently vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 1 dose, expiration date: 14-JUN-2023, administered as prophylaxis (strength, dosage regimen, lot #, and route of administration were not provided) (Expired product administered). The patient did not have any symptom.
Eyes burned and watered, got sick to stomach - was throwing up for about 2 hours, chills, felt flu like symptoms.
Lt thigh has 3" x 2" red, swollen area with 1" x 1" red, swollen area above it. Area warm to touch, soreness. Mother advised to use ice and Benadryl.
Adverse Effect: Guest had an episode of dizziness and passing out per report.  Treatment: Guest lowered the floor, ice pack applied to back of the neck: EMS assessed - juice offered accepted. VSS.  Outcomes:  Guest provided 45 monitoring time, mother with guest. Guest stable and released by EMS to mother's Care.
This spontaneous report as received regarding a 70 years old female patient from her friend. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (lot number, expiry date, dose and route were not reported). On an unknown date, the patient developed an itch and pain all over the body. The outcome of itch and pain all over the body was unknown. Additional information has been requested.
C/O "scratchy throat with lump and itching on chest, neck and left arm". #24 angiocath to right AC. 500 Normal saline up.  Benadry 25mg IVP.  Medrol dose pak called in and patient kept at infusion center x 2 hrs. to monitor.  VS monitored.  Pt d/c to home with family member without incident.
VERTIGO; FATIGUE; PAIN; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031 expiry: UNKNOWN) dose was not reported, administered on 18-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 19-MAR-2021, the subject experienced pain. On 20-MAR-2021, the subject experienced fatigue. On 22-MAR-2021, the subject experienced vertigo. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vertigo, and fatigue on 22-MAR-2021, and pain on 21-MAR-2021. This report was non-serious. This case, from the same reporter is linked to 20210417746.; Sender's Comments: V0:- Medical assessment comment not required as per standard operating procedure as the case assessed as non-serious.
Cough, headache, extremely itchy, red, swollen eyes, upper body aches for 2 days.
on 9/2-9/3/20 patient experiencing short shocking intermittent pain in his stomach and chest.  He said he was dizzy last night.  He stated he and his wife were sweaty for a short time this morning.  Symptoms have not changed in 12 hours.  Office reached out to patient on 9/4/20 by phone and patient portal without response
Attention please investigate my wife recieved the Pfizer Covid 19 vaccine and I got sick after she recieved the vaccine so did my little son who is 7 yrs old. We both have huge headaches and my wife who received both doses showed signs if being sick from the vaccine. Is there currently any trials to determine if people who get the vaccine can transmit the attenuated virus? I believe that the Pfizer vaccine got me and my son sick after my wife got the 2nd shot. Please investigate and stop this vaccine before it causes more transmission of the virus.
No additional AE.; HCP reporting a patient was administered MMRII intramuscularly instead of subcutaneously.; This spontaneous report was received from a pharmacist regarding a patient of an unknown age and gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 17-NOV-2022, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) 0.5 ml, once, lot #W023075, expiration date: 05-APR-2024, administered intramuscularly instead of subcutaneously for prophylaxis (Incorrect route of product administration). There was no adverse event reported.
This spontaneous report was received from the registered nurse refers to an unknown number of patients of unknown age and gender. On an unknown date, the patient was vaccinated with RECOMBIVAX HB (dose, route and lot were not reported). On an unknown date, the patients received improperly stored RECOMBIVAX  HB. No adverse symptoms reported.  At the time of the report the action taken was not reported. Additional information has been requested.
No reported patient side effects.; expired dose of PNEUMOVAX 23 was administered to a patient on 2/7/23 but expired on 1/13/23.; This spontaneous report was received from a pharmacist and referred to a 75-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, drug reactions and allergies were not reported.  On 07-FEB-2023, the patient was vaccinated with an expired dose of  pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23), 0.5 milliliter(mL) injection, 0.5 milliliter, lot #U021995, expiration date: 13-JAN-2023, administered subcutaneously (SQ) for prophylaxis (expired product administered). Pharmacist confirmed that expired vaccine administered had never been stored out of temperature range therefore has never had a temperature excursion. No reported patient side effects. Information regarding revaccination provided to the pharmacist as requested.
Dose 1 moderna 03/12/2021 031A21aA lot  Currently has Covid 19
Body aches, chills, headache, nausea within 16-24 after receiving vaccine.  All symptoms resolved within 48 hours after receiving the vaccine.
approx 17mos p/vax pt devel chickenpox w/less than 50 red, raised lesions that did not itch or scab over. on approx 6oct98 pt devel 2nd case of chickenpox
Initial unsolicited literature report received from a physician on 16 June 2015. This case is linked to 2015SA092506, 2015SA092507, 2015SA092508, 2015SA092509, 2015SA092510, 2015SA092511, 2015SA092512, 2015SA089479, 2015SA092722, 2015SA092724, 2015SA092725 (same vaccine). ). Abstracts: Objective: To evaluate pregnancy outcomes of women who received Tdap vaccination at or after 32 weeks of gestation. Outcomes from consecutive pregnancies during which the mother received Tdap were also analyzed. Methods: In a retrospective cohort study at a single institution, we compared pregnancy outcomes between those who accepted or declined Tdap at 32 weeks of gestation. Additionally, women who received Tdap vaccination in this and a prior pregnancy in the past 5 years were compared with multiparous women who only received Tdap in this pregnancy. Results: Since 2013, 7,378 women who were offered the Tdap vaccine antenatally delivery at our institution: 7,152 accepted (97 percentage). There was no difference in stillbirths, major malformations, chorioamnionitis, 5-minute Apgar score, or cord blood pH. Neonatal complications including ventilation requirement, sepsis, intraventricular hemorrhage, and neonatal death were also similar. However, preterm birth rates at 36 weeks of gestation or less (6 percentage compared with 12 percentage, P less than 0.001), incidence of small for gestational age (10 percentage compare with 15 percentage, P equal to 03), and length of neonatal hospitalization (3.9 compared with 4.7 days, P less than 001) were all significantly increased in the unvaccinated cohort. No difference in neonatal outcomes was noted between women who were administered at lest two Tdap vaccines in the past 5 years (n equal to 1,229) and those who received only a single dose (n equal to 4,159). Conclusion: No adverse pregnancy outcomes were identified in association with antepartum Tdap vaccination. This remained true in women receiving more than one Tdap vaccine in a 5-year timeframe. This may be the result of a type II error. A 7,378 number of female patients out of which (97 percentage) patients received Tdap vaccine and 226 (3 percentage) patients declined Tdap vaccine. A 7,152 number of female patients, whose medical history and concomitant medication were not reported had received a dose of Tdap (batch number, expiration date, dose, dose number, route and site of administration were not reported) on an unspecified date. As Tdap vaccine was exposure in utero, thus 50 (0.7 perentage) neonate patients had blood pH 7.0 or less. Laboratory investigation and corrective treatment were not reported. At the time of this report, the outcome of the event was unknown. Documents held by sender: none.
This spontaneous report as received from a certified medical assistant refers to a patient of unknown demographics. On an unknown date, the patient was vaccinated with a dose of improperly stored GARDASIL (Lot number, expiry date, route and dose were not reported). The certified medical assistant reported that the vaccine was exposed to temperature of 26 F (Fahrenheit)for a total of 135 hours. No adverse effects reported. Follow-up received. Certified Medical assistant stated that other 104 children received GARDASIL. Follow up information has been received from the certified medical assistant regarding a 14 years old, male patient with no pertinent medical history reported. On 31-AUG-2012 the patient was vaccinated with a dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). On 26-NOV-2012 the patient received another dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). On 21-MAR-2013 the patient received another dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the left arm, dose not reported). It was reported that the patient did not seek medical attention. This is one of the several reports from the same source. Additional information is not expected.
Muscle twitching in left tricep below injection site.  Started 5 days after injection and has persisted for 6 days. Comes and goes 24x7. Not painful. Seems to have subsided today (day6) and preceding night.
Initial report received on 06 July 2009 from a physician. A 57-year-old female patient, who has allergy to bee stings and pesticides, but no known drug allergies, had received a dose of ADACEL (lot number, route and site not reported) on 02 July 2009. The patient was taking concomitant medication LIPITOR (indication not reported), and had not received any other vaccinations within four weeks of 02 July 2009. One hour post-vaccination on 02 July 2009, the patient reported hives, facial swelling, and shortness of breath. The patient was evaluated by a physician and placed on PREDNISONE 60-60-40-40 dosing. On 05 July 2009 the patient began having swelling of knee (side not reported). The following day, the knee was better, but the left hand was swollen and painful. It was unknown if the patient had any relevant diagnostic test or if any laboratory data had been performed. Other treatments received were not reported. At the time of this report, it was unknown if the patient had recovered. Documents held by sender: None.
Approx. 7-10 days after vaccine patient noticed a rash around corner of mouth and R eye swelling.
allergic reaction of itchy red bumps on body and head; chills; fever; bad headaches and got worse; cough; chest congestion; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills), PYREXIA (fever), HEADACHE (bad headaches and got worse), COUGH (cough) and CHEST DISCOMFORT (chest congestion) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced CHILLS (chills), PYREXIA (fever), HEADACHE (bad headaches and got worse), COUGH (cough) and CHEST DISCOMFORT (chest congestion). On an unknown date, the patient experienced RASH PRURITIC (allergic reaction of itchy red bumps on body and head). The patient was treated with LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) at an unspecified dose and frequency. On 09-Jan-2021, CHILLS (chills), HEADACHE (bad headaches and got worse), COUGH (cough) and CHEST DISCOMFORT (chest congestion) had resolved. At the time of the report, PYREXIA (fever) and RASH PRURITIC (allergic reaction of itchy red bumps on body and head) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.    Most recent FOLLOW-UP information incorporated above includes: On 27-Jan-2021: No specific follow-up information recorded.
HIVES ON LEFT ARM (RED AND SWOLLEN), SWOLLEN LYMPH NODES, HEADACHE, BODYACHES, FATIGUE
This is a spontaneous report from a contactable physician via Pfizer sales representative. A 8-decade-old female patient received received pneumococcal PREVNAR 13, via an unspecified route of administration on unspecified date at a single dose for immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced swelling at the injection site on an unspecified date. Outcome of the event was unknown. No follow-up attempts are possible, information about batch number cannot be obtained.
This spontaneous report as received from a registered nurse refers to a 3 years old male patient without drug reactions or allergies. The patient has no pertinent medical history. The patient was vaccinated one 0.5ml dose of VARIVAX (lot number 665691/1236Y; expired date 27-AUG-2011) subcutaneously on 26-MAR-2010. No other co-suspects were reported. There were no concomitant medications. On 08-AUG-2012 the patient was seen in the office and diagnosed with a mild case of chickenpox. The patient had less than 50 widespread lesions. The patient was directed to take BENADRYL as treatment for the adverse event. There was no laboratory diagnostics study performed. The patient was recovering at the time of report. The patient had visit the office for medical attention. Additional information is not expected.
Patient has been experiencing a nasty reaction to the vaccine, has had redness, swelling of 5 inches in diameter, and has tenderness, burning, itching, and pain at the injection site for over 5 days.
Janssen COVID-19 Vaccine EUA. About 8 hours after I got the vaccine I got a fever of 101 with chills and achiness and tiredness. The next day my fever was 101.5. the chills went away but achiness was still there.
Describe adverse reaction: After administration at 15:45,  patient hyperextended her neck/ head tilted back. Inhaled deeply, exhaled deeply, became pale and flushed in cheeks. Patient complained of pressure in her head. Transferred to wheeled chair , and moved to private holding room in Covid Vaccine Clinic. Pt complained of dizziness. Transferred with assistance to gurnee.   AT 15:46: BP 153/98 in RA Pulse ox 95%, Heart rate 91 bpm, after just being placed in gurnee. Offered water, juice, and crackers. she declined. HOB at 45 degrees  AT 15:53 vitals were: BP 147/59, pulse ox 96%, Heart rate 89bpm. Pt states less dizziness, and feeling a bit better.   At 16:16: BP 148/84, Heart rate 86, Pulse ox 94%. Patient denies dizziness and headache. Says she is feeling better. Brough to sit at edge of bed for a minute. Standing for one minute. Then ambulating about room without dizziness. Patient states she feels okay to go home. Left to home with family member, who would be driving patient home.
Patient complained of "normal, typical" soreness in right deltoid area the day after receiving Afluria Influenza vaccine. However, the soreness continued and spread throughout right upper arm/right deltoid area. Patient reported the persistent soreness on 11/6/23. She stated the affected area bothers her when she moves her arm  and is tender to touch. Denies any numbness/tingling to right arm. Denies any swelling to right deltoid area, but states it feels warm to her (skin warmth was not detected on exam).
Within fifteen minutes of receiving her vaccines, patient became flushed and felt short of breath.  She had nausea.  She was laid down.  Her oxygen sat on room air was 95%.  She was placed on 2 liters of oxygen by face mask and her oxygen sat improved to 100%.  EMS was called.  Her chest tightness resolved within five minutes as did her flushing.  She then experienced extreme back pain and felt nauseous again.  At that time paramedics arrived and transported her to the emergency room.
Patient with induration at the site of vaccination as well as redness and warmth over the entire arm above elbow.
No reaction to vaccines - contracted Covid about 3 months after 2nd Booster Shot.  Sneezing, runny nose, coughing,
This spontaneous report as received from a registered nurse refers to a patients of unkonwn age and gender. The patients medical history and current conditions were not provided. On an unknown dates, the patients were vaccinated with a dose of RECOMBIVAX HB (doses and routes were not reported) lot # J009051, expiration date 26-MAR-2016, that were exposed to temperatures outside of the recommended range. The registered nurse was not aware of any adverse effects. This is one of several reports received from the same reporter. Additional information has been requested.
At well child visit on 5/2/2012 parent reported that child had whole arm swelling starting 2 hours following vaccination.  Lasted for 10 days.  Arm became red, swollen and painful.  Missed a few days of school.  Parent stated that child has a similar episode after receiving influenza vaccine the year prior.  Received Fluarix 10/22/2010 in left deltoid.